Gallium-68 Citrate PET Used in Prostate Cancer

Recruiting in Palo Alto (17 mi)

Overseen byRahul Aggarwal, MD

Age: 18+

Sex: Male

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Waitlist Available

Sponsor: Rahul Aggarwal

No Placebo Group

Trial Summary

What is the purpose of this trial?This is a single center, pilot, cross-sectional imaging study investigating the use of gallium-68 citrate PET in participants with metastatic castration-resistant prostate cancer who are planning to undergo a metastatic tumor biopsy on protocol NCT02432001 (CC#125519). The study population will consist of participants with metastatic castration-resistant prostate cancer who are undergoing a metastatic tumor biopsy as part of clinical protocol NCT02432001 (CC#125519), with evidence of resistance to androgen signaling inhibition.

Eligibility Criteria

Inclusion Criteria

Male participants with histologically confirmed prostate cancer

Participants must have castrate levels of testosterone (< 50 ng/dL) on Luteinizing hormone-releasing hormone (LHRH) analogue or have had prior bilateral orchiectomy, with evidence of castration-resistant disease by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria

Age 18 years or older at the time of study entry

+2 more

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Gallium-68 citrate, PETExperimental Treatment2 Interventions

Participants will receive a single scan obtained on a single day, followed by optional tumor biopsy within 6 weeks of scan. There will be optional follow up gallium-68 citrate PET scan to assess response to treatment received outside this study that will be completed within 12 weeks of baseline scan.